RU2006113948A - Производные пиридина и их применение в качестве антагонистов уротензина ii - Google Patents
Производные пиридина и их применение в качестве антагонистов уротензина ii Download PDFInfo
- Publication number
- RU2006113948A RU2006113948A RU2006113948/04A RU2006113948A RU2006113948A RU 2006113948 A RU2006113948 A RU 2006113948A RU 2006113948/04 A RU2006113948/04 A RU 2006113948/04A RU 2006113948 A RU2006113948 A RU 2006113948A RU 2006113948 A RU2006113948 A RU 2006113948A
- Authority
- RU
- Russia
- Prior art keywords
- ethyl
- ureido
- piperidin
- dimethylpyridin
- aryl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- -1 pyridin-4-yl radical Chemical class 0.000 claims 108
- 150000001875 compounds Chemical class 0.000 claims 35
- 239000001257 hydrogen Substances 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 19
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 18
- 125000002837 carbocyclic group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- DEVUYWTZRXOMSI-UHFFFAOYSA-N (sulfamoylamino)benzene Chemical compound NS(=O)(=O)NC1=CC=CC=C1 DEVUYWTZRXOMSI-UHFFFAOYSA-N 0.000 claims 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 238000002399 angioplasty Methods 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 208000007056 sickle cell anemia Diseases 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 200000000007 Arterial disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010059109 Cerebral vasoconstriction Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000035202 High altitude pulmonary edema Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 2
- 206010038419 Renal colic Diseases 0.000 claims 2
- 206010063897 Renal ischaemia Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 2
- 206010051895 acute chest syndrome Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000018631 connective tissue disease Diseases 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 208000001286 intracranial vasospasm Diseases 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000000877 morphologic effect Effects 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000018360 neuromuscular disease Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 208000007232 portal hypertension Diseases 0.000 claims 2
- 208000005333 pulmonary edema Diseases 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000013223 septicemia Diseases 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000006016 thyroid dysfunction Effects 0.000 claims 2
- 206010044008 tonsillitis Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- JWWGZUNNEIUCNE-UHFFFAOYSA-N 1-(2,6-dimethylpyridin-4-yl)-3-[2-(3,3-diphenylpyrrolidin-1-yl)ethyl]urea Chemical compound CC1=NC(C)=CC(NC(=O)NCCN2CC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 JWWGZUNNEIUCNE-UHFFFAOYSA-N 0.000 claims 1
- FFIHDYBQWKZAKX-UHFFFAOYSA-N 1-(2,6-dimethylpyridin-4-yl)-3-[2-[4-[methyl-[4-(trifluoromethyl)phenyl]sulfonylamino]piperidin-1-yl]ethyl]urea Chemical compound C=1C=C(C(F)(F)F)C=CC=1S(=O)(=O)N(C)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 FFIHDYBQWKZAKX-UHFFFAOYSA-N 0.000 claims 1
- WCPFQQHADRJANG-UHFFFAOYSA-N 1-(4-methoxyphenyl)cyclopropane-1-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1(C(O)=O)CC1 WCPFQQHADRJANG-UHFFFAOYSA-N 0.000 claims 1
- CUTGZUCYQMNVJF-UHFFFAOYSA-N 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2,6-diethylpyridin-4-yl)urea Chemical compound CCC1=NC(CC)=CC(NC(=O)NCCN2CCC(O)(CC=3C=CC=CC=3)CC2)=C1 CUTGZUCYQMNVJF-UHFFFAOYSA-N 0.000 claims 1
- YTDCFWNNOYWQHK-UHFFFAOYSA-N 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2,6-dimethylpyridin-4-yl)urea Chemical compound CC1=NC(C)=CC(NC(=O)NCCN2CCC(O)(CC=3C=CC=CC=3)CC2)=C1 YTDCFWNNOYWQHK-UHFFFAOYSA-N 0.000 claims 1
- QADSWFUWTFRSTI-UHFFFAOYSA-N 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-ethyl-6-methylpyridin-4-yl)urea Chemical compound CC1=NC(CC)=CC(NC(=O)NCCN2CCC(O)(CC=3C=CC=CC=3)CC2)=C1 QADSWFUWTFRSTI-UHFFFAOYSA-N 0.000 claims 1
- CGVXZQKFKMHDPG-UHFFFAOYSA-N 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-[2-(2-phenylethyl)pyridin-4-yl]urea Chemical compound C1CN(CCNC(=O)NC=2C=C(CCC=3C=CC=CC=3)N=CC=2)CCC1(O)CC1=CC=CC=C1 CGVXZQKFKMHDPG-UHFFFAOYSA-N 0.000 claims 1
- GSXUSXKCHSEEFG-UHFFFAOYSA-N 1-[2-(4-benzylpiperidin-1-yl)ethyl]-3-(2,6-diethylpyridin-4-yl)urea Chemical compound CCC1=NC(CC)=CC(NC(=O)NCCN2CCC(CC=3C=CC=CC=3)CC2)=C1 GSXUSXKCHSEEFG-UHFFFAOYSA-N 0.000 claims 1
- JOVBOQDTDWCQJQ-UHFFFAOYSA-N 1-[2-(4-benzylpiperidin-1-yl)ethyl]-3-(2,6-dimethylpyridin-4-yl)urea Chemical compound CC1=NC(C)=CC(NC(=O)NCCN2CCC(CC=3C=CC=CC=3)CC2)=C1 JOVBOQDTDWCQJQ-UHFFFAOYSA-N 0.000 claims 1
- PMUVJCPXPHGZFL-UHFFFAOYSA-N 1-[2-(4-benzylpiperidin-1-yl)ethyl]-3-(2-ethyl-6-methylpyridin-4-yl)urea Chemical compound CC1=NC(CC)=CC(NC(=O)NCCN2CCC(CC=3C=CC=CC=3)CC2)=C1 PMUVJCPXPHGZFL-UHFFFAOYSA-N 0.000 claims 1
- SDQLDPOOXOLSDM-UHFFFAOYSA-N 1-[2-(4-benzylpiperidin-1-yl)ethyl]-3-(2-methyl-6-propylpyridin-4-yl)urea Chemical compound CC1=NC(CCC)=CC(NC(=O)NCCN2CCC(CC=3C=CC=CC=3)CC2)=C1 SDQLDPOOXOLSDM-UHFFFAOYSA-N 0.000 claims 1
- DCFCZRYWKJJHAW-UHFFFAOYSA-N 1-[2-[(2-methyl-6-propylpyridin-4-yl)carbamoylamino]ethyl]-4-phenyl-N-(2-phenylethyl)piperidine-4-carboxamide Chemical compound C(C1=CC=CC=C1)CNC(=O)C1(CCN(CC1)CCNC(=O)NC1=CC(=NC(=C1)CCC)C)C1=CC=CC=C1 DCFCZRYWKJJHAW-UHFFFAOYSA-N 0.000 claims 1
- QIQVSDKBVFEASF-UHFFFAOYSA-N 1-[2-[4-(cyclopropylamino)piperidin-1-yl]ethyl]-3-(2,6-dimethylpyridin-4-yl)urea Chemical compound CC1=NC(C)=CC(NC(=O)NCCN2CCC(CC2)NC2CC2)=C1 QIQVSDKBVFEASF-UHFFFAOYSA-N 0.000 claims 1
- GBDCYEMRIVDQFP-UHFFFAOYSA-N 1-[2-[4-[(2,6-difluorophenyl)sulfonyl-ethylamino]piperidin-1-yl]ethyl]-3-(2,6-dimethylpyridin-4-yl)urea Chemical compound FC=1C=CC=C(F)C=1S(=O)(=O)N(CC)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 GBDCYEMRIVDQFP-UHFFFAOYSA-N 0.000 claims 1
- GUNHYCLKBCIWEX-UHFFFAOYSA-N 1-[2-[4-[(3,4-difluorophenyl)sulfonyl-ethylamino]piperidin-1-yl]ethyl]-3-(2,6-dimethylpyridin-4-yl)urea Chemical compound C=1C=C(F)C(F)=CC=1S(=O)(=O)N(CC)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 GUNHYCLKBCIWEX-UHFFFAOYSA-N 0.000 claims 1
- KOUVYYQUIQJPCK-UHFFFAOYSA-N 1-[2-[4-[(3,4-dimethoxyphenyl)sulfonyl-ethylamino]piperidin-1-yl]ethyl]-3-(2,6-dimethylpyridin-4-yl)urea Chemical compound C=1C=C(OC)C(OC)=CC=1S(=O)(=O)N(CC)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 KOUVYYQUIQJPCK-UHFFFAOYSA-N 0.000 claims 1
- ARHYSDQOKXDTRM-UHFFFAOYSA-N 1-[2-[4-[ethyl-(4-fluorophenyl)sulfonylamino]piperidin-1-yl]ethyl]-3-(2-ethyl-6-methylpyridin-4-yl)urea Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CC)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(CC)=C1 ARHYSDQOKXDTRM-UHFFFAOYSA-N 0.000 claims 1
- CVTJRDGIBFGYGG-ISLYRVAYSA-N 1-[2-[[2-methyl-6-[(E)-2-phenylethenyl]pyridin-4-yl]carbamoylamino]ethyl]-4-phenyl-N-(2-phenylethyl)piperidine-4-carboxamide Chemical compound C(C1=CC=CC=C1)CNC(=O)C1(CCN(CC1)CCNC(=O)NC1=CC(=NC(=C1)\C=C\C1=CC=CC=C1)C)C1=CC=CC=C1 CVTJRDGIBFGYGG-ISLYRVAYSA-N 0.000 claims 1
- OVDCPMIQPLSSCB-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-n-ethylacetamide Chemical compound C=1C=CC=C(Cl)C=1CC(=O)N(CC)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 OVDCPMIQPLSSCB-UHFFFAOYSA-N 0.000 claims 1
- MVJFNFSHWVBTDT-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-n-ethylacetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1CC(=O)N(CC)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 MVJFNFSHWVBTDT-UHFFFAOYSA-N 0.000 claims 1
- KIPNWRXDRIBHAF-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-n-methylacetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1CC(=O)N(C)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 KIPNWRXDRIBHAF-UHFFFAOYSA-N 0.000 claims 1
- ZQXQFYWYBKAKGS-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-n-methylacetamide Chemical compound C=1C=CC(Cl)=CC=1CC(=O)N(C)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 ZQXQFYWYBKAKGS-UHFFFAOYSA-N 0.000 claims 1
- CJVJLTYACWMABY-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-n-ethyl-2-methylpropanamide Chemical compound C=1C=C(Cl)C=CC=1C(C)(C)C(=O)N(CC)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 CJVJLTYACWMABY-UHFFFAOYSA-N 0.000 claims 1
- GJCDSCBDXBCGGJ-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-n-methylacetamide Chemical compound C=1C=C(Cl)C=CC=1CC(=O)N(C)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 GJCDSCBDXBCGGJ-UHFFFAOYSA-N 0.000 claims 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- NEITTXGOPHZMPA-UHFFFAOYSA-N CC1=CC(NC(NCCN(CC2)CCC2NC)=O)=CC(C)=N1.COC1=CC=C(C2(CC2)C(O)=O)C=C1 Chemical compound CC1=CC(NC(NCCN(CC2)CCC2NC)=O)=CC(C)=N1.COC1=CC=C(C2(CC2)C(O)=O)C=C1 NEITTXGOPHZMPA-UHFFFAOYSA-N 0.000 claims 1
- HQKPAFRNSDOWOS-UHFFFAOYSA-N CC1=CC(NC(NCCN(CC2)CCC2NC)=O)=CC(C)=N1.OS(C(C=C(S1)Cl)=C1Cl)(=O)=O Chemical compound CC1=CC(NC(NCCN(CC2)CCC2NC)=O)=CC(C)=N1.OS(C(C=C(S1)Cl)=C1Cl)(=O)=O HQKPAFRNSDOWOS-UHFFFAOYSA-N 0.000 claims 1
- QKVJGAFMMQTKNF-UHFFFAOYSA-N CC1=NC(C)=CC(NC(NCCN(CC2)CCC2NC2CC2)=O)=C1.OS(C(C=C(S1)Cl)=C1Cl)(=O)=O Chemical compound CC1=NC(C)=CC(NC(NCCN(CC2)CCC2NC2CC2)=O)=C1.OS(C(C=C(S1)Cl)=C1Cl)(=O)=O QKVJGAFMMQTKNF-UHFFFAOYSA-N 0.000 claims 1
- XXPRDLKEYXGEIG-UHFFFAOYSA-N CCC1=NC(C)=CC(NC(NCCN(CC2)CCC2NCC)=O)=C1.OC(C1(CC1)C(C=C1)=CC=C1Cl)=O Chemical compound CCC1=NC(C)=CC(NC(NCCN(CC2)CCC2NCC)=O)=C1.OC(C1(CC1)C(C=C1)=CC=C1Cl)=O XXPRDLKEYXGEIG-UHFFFAOYSA-N 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102000050488 Urotensin II Human genes 0.000 claims 1
- 108010018369 Urotensin II Proteins 0.000 claims 1
- 102000012327 Urotensin II receptors Human genes 0.000 claims 1
- 108050002984 Urotensin II receptors Proteins 0.000 claims 1
- 229940116211 Vasopressin antagonist Drugs 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 231100000867 compulsive behavior Toxicity 0.000 claims 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- ALTNTMJNLJJZEN-UHFFFAOYSA-N n-[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-2-(4-fluorophenyl)-n-methylacetamide Chemical compound C=1C=C(F)C=CC=1CC(=O)N(C)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 ALTNTMJNLJJZEN-UHFFFAOYSA-N 0.000 claims 1
- OXVUFFOIIQSRDL-UHFFFAOYSA-N n-[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-n-ethyl-2-phenylacetamide Chemical compound C=1C=CC=CC=1CC(=O)N(CC)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 OXVUFFOIIQSRDL-UHFFFAOYSA-N 0.000 claims 1
- CSAIONXNBLYFIZ-UHFFFAOYSA-N n-[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-n-ethyl-2-thiophen-2-ylacetamide Chemical compound C=1C=CSC=1CC(=O)N(CC)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 CSAIONXNBLYFIZ-UHFFFAOYSA-N 0.000 claims 1
- GMPQCZOSOZDVEK-UHFFFAOYSA-N n-[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-n-ethyl-3,4-dimethoxybenzamide Chemical compound C=1C=C(OC)C(OC)=CC=1C(=O)N(CC)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 GMPQCZOSOZDVEK-UHFFFAOYSA-N 0.000 claims 1
- PVAFEQHVEAVCJP-UHFFFAOYSA-N n-[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-n-ethyl-4-fluorobenzamide Chemical compound C=1C=C(F)C=CC=1C(=O)N(CC)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 PVAFEQHVEAVCJP-UHFFFAOYSA-N 0.000 claims 1
- RZPNUNDXIUUBNP-UHFFFAOYSA-N n-[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-n-methyl-2-phenylacetamide Chemical compound C=1C=CC=CC=1CC(=O)N(C)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(C)=C1 RZPNUNDXIUUBNP-UHFFFAOYSA-N 0.000 claims 1
- SDBCDGMASFQENW-UHFFFAOYSA-N n-[4-[[1-[2-[(2,6-dimethylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]methylsulfamoyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NCC1CCN(CCNC(=O)NC=2C=C(C)N=C(C)C=2)CC1 SDBCDGMASFQENW-UHFFFAOYSA-N 0.000 claims 1
- LPCFSSAXQPCDLB-UHFFFAOYSA-N n-ethyl-n-[1-[2-[(2-ethyl-6-methylpyridin-4-yl)carbamoylamino]ethyl]piperidin-4-yl]-2-phenylacetamide Chemical compound C=1C=CC=CC=1CC(=O)N(CC)C(CC1)CCN1CCNC(=O)NC1=CC(C)=NC(CC)=C1 LPCFSSAXQPCDLB-UHFFFAOYSA-N 0.000 claims 1
- 239000003614 peroxisome proliferator Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- HFNHAPQMXICKCF-USJMABIRSA-N urotensin-ii Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@@H](C(C)C)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O HFNHAPQMXICKCF-USJMABIRSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 239000003038 vasopressin antagonist Substances 0.000 claims 1
- 0 CC(C)(CC1(C)C)CN(CCNC(N*)=O)CCC1(*)I Chemical compound CC(C)(CC1(C)C)CN(CCNC(N*)=O)CCC1(*)I 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP03/10746 | 2003-09-26 | ||
| EP0310746 | 2003-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006113948A true RU2006113948A (ru) | 2007-11-10 |
Family
ID=34384524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006113948/04A RU2006113948A (ru) | 2003-09-26 | 2004-09-21 | Производные пиридина и их применение в качестве антагонистов уротензина ii |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7750161B2 (enExample) |
| EP (1) | EP1670470B1 (enExample) |
| JP (1) | JP4851328B2 (enExample) |
| KR (1) | KR20070014108A (enExample) |
| CN (1) | CN1856305B (enExample) |
| AR (1) | AR045949A1 (enExample) |
| AT (1) | ATE427748T1 (enExample) |
| AU (1) | AU2004275488A1 (enExample) |
| BR (1) | BRPI0414777A (enExample) |
| CA (1) | CA2540196C (enExample) |
| DE (1) | DE602004020486D1 (enExample) |
| IL (1) | IL174497A0 (enExample) |
| MX (1) | MXPA06003264A (enExample) |
| NO (1) | NO20061395L (enExample) |
| RU (1) | RU2006113948A (enExample) |
| TW (1) | TW200526630A (enExample) |
| WO (1) | WO2005030209A1 (enExample) |
| ZA (1) | ZA200602442B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004089296A2 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| DE10358539A1 (de) * | 2003-12-15 | 2005-07-07 | Merck Patent Gmbh | Carbonsäureamidderivate |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| AR051213A1 (es) * | 2004-10-12 | 2006-12-27 | Actelion Pharmaceuticals Ltd | 1-(2-(4-bencil-4-hidroxi-piperidin-1-il)-etil)-3-(2-metil-quinolin-4-il)-urea como una sal sulfato cristalina |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| WO2006045119A2 (en) | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| SE0403084D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Chemical process |
| WO2006135694A2 (en) * | 2005-06-10 | 2006-12-21 | Acadia Pharmaceuticals Inc. | Uii-modulating compounds and their use |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| WO2007118853A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| AU2007337659A1 (en) * | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd. | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
| WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| AU2008335135A1 (en) | 2007-12-11 | 2009-06-18 | Cytopathfinder, Inc. | Carboxamide compounds and their use as chemokine receptor agonists |
| EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI97540C (fi) | 1989-11-06 | 1997-01-10 | Sanofi Sa | Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi |
| US6159700A (en) | 1997-01-27 | 2000-12-12 | Smithkline Beecham Corporation | Method of finding agonist and antagonist to human and rat GPR14 |
| AUPP003197A0 (en) | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| HK1044282A1 (zh) * | 1998-12-18 | 2002-10-18 | Bristol-Myers Squibb Pharma Company | 作为趋化因子受体活性调节剂的n-脲基烷基-哌啶化合物 |
| US6331541B1 (en) * | 1998-12-18 | 2001-12-18 | Soo S. Ko | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| AU6339200A (en) | 1999-07-28 | 2001-02-19 | Kirin Beer Kabushiki Kaisha | Urea derivatives as inhibitors of ccr-3 receptor |
| JP2003518059A (ja) | 1999-12-21 | 2003-06-03 | スミスクライン・ビーチャム・コーポレイション | ウロテンシン−ｉｉ受容体アンタゴニスト |
| US6544992B1 (en) | 1999-12-21 | 2003-04-08 | Smithkline Beecham Corporation | Urotensin-II receptor antagonists |
| CA2394603A1 (en) | 1999-12-21 | 2001-06-28 | Dashyant Dhanak | Urotensin-ii receptor antagonists |
| EP1262195A4 (en) | 2000-03-07 | 2003-05-21 | Takeda Chemical Industries Ltd | VASOACTIVE AGENTS |
| AU2001271357A1 (en) * | 2000-06-21 | 2002-01-02 | Dupont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| WO2002000606A1 (en) | 2000-06-28 | 2002-01-03 | Takeda Chemical Industries, Ltd. | Biphenyl compound |
| AU2001271018A1 (en) | 2000-07-04 | 2002-01-14 | Takeda Chemical Industries Ltd. | Gpr14 antagonist |
| EP1351688A4 (en) | 2000-12-11 | 2006-01-04 | Smithkline Beecham Corp | UROTENSIN-II RECEPTOR ANTAGONISTS |
| AU2002239506A1 (en) | 2000-12-11 | 2002-06-24 | Smith Kline Beecham Corporation | Urotensin-ii receptor antagonists |
| US6818655B2 (en) | 2001-01-26 | 2004-11-16 | Smithkline Beecham Corporation | Urotensin-II receptor antagonists |
| JP2004529132A (ja) | 2001-03-27 | 2004-09-24 | アクテリオン ファマシューティカルズ リミテッド | １，２，３，４−テトラヒドロイソキノリン誘導体 |
| WO2002078707A1 (en) | 2001-03-29 | 2002-10-10 | Smithkline Beecham Corporation | Pyrrolidine sulfonamides |
| WO2002078641A2 (en) | 2001-03-29 | 2002-10-10 | Smithkline Beecham Corporation | Pyrrolidine sulfonamides |
| JP2004525156A (ja) | 2001-03-29 | 2004-08-19 | スミスクライン・ビーチャム・コーポレイション | ピロリジンスルホンアミド |
| US20040152692A1 (en) | 2001-03-29 | 2004-08-05 | Dashyant Dhanak | Pyrrolidine sulfonamides |
| JP2004529170A (ja) | 2001-05-07 | 2004-09-24 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| AR033879A1 (es) | 2001-05-07 | 2004-01-07 | Smithkline Beecham Corp | Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto |
| WO2002090337A1 (en) | 2001-05-07 | 2002-11-14 | Smithkline Beecham Corporation | Sulfonamides |
| EP1387679A4 (en) | 2001-05-07 | 2004-08-11 | Smithkline Beecham Corp | SULPHONAMIDES |
| WO2002089740A2 (en) | 2001-05-07 | 2002-11-14 | Smithkline Beecham Corporation | Sulfonamides |
| US6849635B2 (en) | 2001-05-07 | 2005-02-01 | Smithkline Beecham Corporation | Sulfonamides |
| CA2473892C (en) * | 2001-12-04 | 2010-09-21 | Actelion Pharmaceuticals Ltd | Novel quinoline derivatives |
| KR20050043967A (ko) * | 2002-09-17 | 2005-05-11 | 액테리온 파마슈티칼 리미티드 | 1-피리딘-4-일-요소 유도체 |
| AR041885A1 (es) | 2002-11-06 | 2005-06-01 | Smithkline Beecham Corp | Compuesto de sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion |
| WO2004043369A2 (en) | 2002-11-06 | 2004-05-27 | Smithkline Beecham Corporation | Sulfonamides |
| WO2004043917A1 (en) | 2002-11-06 | 2004-05-27 | Smithkline Beecham Corporation | Sulfonamides |
| AU2003295408A1 (en) | 2002-11-06 | 2004-06-03 | Smithkline Beecham Corporation | Sulfonamides |
| WO2004043366A2 (en) | 2002-11-06 | 2004-05-27 | Smithkline Beecham Corporation | Sulfonamides |
| WO2004073634A2 (en) | 2003-02-20 | 2004-09-02 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| WO2004099179A1 (en) * | 2003-05-07 | 2004-11-18 | Actelion Pharmaceuticals Ltd | Piperazine-alkyl-ureido derivatives |
-
2004
- 2004-09-21 JP JP2006527332A patent/JP4851328B2/ja not_active Expired - Fee Related
- 2004-09-21 DE DE602004020486T patent/DE602004020486D1/de not_active Expired - Lifetime
- 2004-09-21 BR BRPI0414777-4A patent/BRPI0414777A/pt not_active Application Discontinuation
- 2004-09-21 MX MXPA06003264A patent/MXPA06003264A/es unknown
- 2004-09-21 EP EP04765436A patent/EP1670470B1/en not_active Expired - Lifetime
- 2004-09-21 AT AT04765436T patent/ATE427748T1/de not_active IP Right Cessation
- 2004-09-21 KR KR1020067005848A patent/KR20070014108A/ko not_active Withdrawn
- 2004-09-21 AU AU2004275488A patent/AU2004275488A1/en not_active Abandoned
- 2004-09-21 US US10/573,516 patent/US7750161B2/en not_active Expired - Fee Related
- 2004-09-21 RU RU2006113948/04A patent/RU2006113948A/ru unknown
- 2004-09-21 CN CN2004800277254A patent/CN1856305B/zh not_active Expired - Fee Related
- 2004-09-21 WO PCT/EP2004/010559 patent/WO2005030209A1/en not_active Ceased
- 2004-09-21 CA CA2540196A patent/CA2540196C/en not_active Expired - Fee Related
- 2004-09-24 AR ARP040103475A patent/AR045949A1/es unknown
- 2004-09-24 TW TW093129149A patent/TW200526630A/zh unknown
-
2006
- 2006-03-22 IL IL174497A patent/IL174497A0/en unknown
- 2006-03-24 ZA ZA200602442A patent/ZA200602442B/en unknown
- 2006-03-27 NO NO20061395A patent/NO20061395L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004020486D1 (de) | 2009-05-20 |
| AR045949A1 (es) | 2005-11-16 |
| WO2005030209A1 (en) | 2005-04-07 |
| CA2540196A1 (en) | 2005-04-07 |
| CN1856305A (zh) | 2006-11-01 |
| US20070043081A1 (en) | 2007-02-22 |
| TW200526630A (en) | 2005-08-16 |
| IL174497A0 (en) | 2006-08-01 |
| WO2005030209A8 (en) | 2006-05-11 |
| CA2540196C (en) | 2012-03-20 |
| ATE427748T1 (de) | 2009-04-15 |
| JP2007506692A (ja) | 2007-03-22 |
| EP1670470A1 (en) | 2006-06-21 |
| EP1670470B1 (en) | 2009-04-08 |
| AU2004275488A1 (en) | 2005-04-07 |
| MXPA06003264A (es) | 2006-06-08 |
| ZA200602442B (en) | 2007-09-26 |
| NO20061395L (no) | 2006-06-22 |
| JP4851328B2 (ja) | 2012-01-11 |
| KR20070014108A (ko) | 2007-01-31 |
| US7750161B2 (en) | 2010-07-06 |
| CN1856305B (zh) | 2010-04-28 |
| BRPI0414777A (pt) | 2006-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005111589A (ru) | Производные 1-пиридин-4-илмочевины | |
| RU2388750C2 (ru) | Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина | |
| US9409866B2 (en) | Pyridine-2-amides useful as CB2 agonists | |
| JP2006505533A5 (enExample) | ||
| CA2473892A1 (en) | Novel quinoline derivatives | |
| JP2007519754A5 (enExample) | ||
| DE69830410T2 (de) | Meta-benzamidinderivate als serinprotease-inhibitoren | |
| RU2373209C2 (ru) | Пирролотриазиновые соединения как ингибиторы киназ | |
| KR100574109B1 (ko) | 헤테로고리형 티오에스테르 및 케톤 | |
| AU2012266369B2 (en) | Pyridin- 2 -amides useful as CB2 agonists | |
| EP1551810B1 (de) | Diarylsubstituierte cyclische harnstoffderivate mit mch-modulatorischer wirkung | |
| US20070093492A1 (en) | Pyrrolidine derivatives | |
| US20050014748A1 (en) | N-type calcium channel blockers | |
| RU2008112221A (ru) | Соединения ряда изоиндолимидов, их композиции и способы применения | |
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| JP2006513265A5 (enExample) | ||
| CA2457037A1 (en) | Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments | |
| EP1302463A1 (en) | Medicine comprising dicyanopyridine derivative | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| RU2008136553A (ru) | Производные бензотиазола в качестве агонистов бета2 адренорецептора | |
| TW200403058A (en) | Heterocyclo inhibitors of potassium channel function | |
| CA2540196A1 (en) | Pyridine derivatives and use thereof as urotensin ii antagonists | |
| HRP20120069T1 (hr) | Derivati 5,6-bisaril-2-piridinkarboksamida, njihovo dobivanje i njihova upotreba u terapiji kao antagonista receptora urotenzina ii | |
| JP2013509376A5 (enExample) | ||
| JP2013537898A5 (enExample) |